Medovate Ltd, a UK medical device development company based in Cambridge, announced recently that it has been awarded a new group purchasing agreement with Premier, Inc. for its regional anaesthesia system SAFIRA® (SAFer Injection for Regional Anaesthesia).
Premier, Inc. is a healthcare improvement company uniting an alliance of approximately 4,400 US hospitals and health systems and more than 250,000 other providers and organisations. Through approximately 3,000+ negotiated contracts with leading manufacturers, Premier Inc. provides its members with access to one of the strongest contract portfolios in the industry to enable them to make savings on thousands of medical products.
Effective 1st November 2022, the contract allows members of Premier, Inc. to be able to purchase at their discretion the SAFIRA® system through the special pricing and terms pre-negotiated by Premier Inc. in the category of Regional Anaesthesia Trays and Supplies.
Chris Rogers, Sales & Marketing Director at Medovate said: “We are excited to announce that our SAFIRA® system is now available through one of the largest national GPO programmes in the US. This is really positive news for Medovate as it helps streamline the purchase of SAFIRA® for healthcare organisations delivering services and treatments which use regional anaesthesia, such as ambulatory care and surgical centres. It is a great opportunity to increase the availability of our game-changing technology to regional anaesthesia practitioners in the US to help improve patient safety during peripheral nerve blocks.”
The current regional anaesthesia procedure typically requires an assistant to inject the anaesthetic whilst the anaesthetist uses ultrasound guidance to place the needle. SAFIRA® is a novel technology, developed alongside specialist anaesthesia clinicians in the NHS, designed to reduce the risk of nerve injury during regional anaesthesia.
The SAFIRA® system automatically limits injection pressure to a specified threshold to help reduce the risk of nerve injury and improve patient safety. In addition, SAFIRA® transforms regional anaesthesia into a one-person procedure by enablinganaesthetists to conduct the entire nerve block process.
Making regional anaesthesia a single-operator procedure further supports the effective application of resources by enabling the clinician to take full control of the injection process, removing the need for a second operator, freeing up nursing staff to carry out other critical tasks.
SAFIRA® is available across the USA through Medovate’s primary distributor Mercury Medical.